GlassScriptPhysician profile
Stephanie Ideker
NPI 1609213339
$1,278.76
in general payments reported to CMS, 2019-2025
24 companies · $344 in 2025
The $344 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.39 · 2022: $285 · 2023: $416 · 2024: $222 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $883 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $882.68 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $186.55 | 2022-2025 | Lithovue Elite |
| Janssen Biotech, INC. | $150.88 | 2022-2025 | Erleada |
| Astellas Pharma US INC | $139.10 | 2022-2024 | Myrbetriq |
| 180 Medical, INC. | $98.76 | 2022-2024 | Gentlecath |
| Abbvie INC. | $66.41 | 2021-2024 | |
| Antares Pharma, INC. | $64.37 | 2024-2025 | Xyosted |
| Teleflex LLC | $64.37 | 2025 | Barrigel, Urolift |
| Sumitomo Pharma America, INC. | $57.76 | 2024-2025 | Gemtesa, Orgovyx |
| Histosonics, INC. | $51.97 | 2025 | |
| Endo Pharmaceuticals INC. | $49.41 | 2023 | Xiaflex, Aveed |
| Tolmar, INC. | $48.45 | 2023-2025 | Eligard, Jatenzo |
| C. R. Bard, INC. & Subsidiaries | $42.37 | 2025 | Bard Urinary Drainage Bag, Bard Inlay Optima Ureteral Stent With Hydroglide Guidewire |
| Rochester Medical Corporation | $41.67 | 2022 | |
| Medtronic, INC. | $38.32 | 2022-2023 | Interstim |
| Dendreon Pharmaceuticals LLC | $25.57 | 2024 | Provenge |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $20.37 | 2023 | |
| Kci USA, INC. | $19.65 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $19.27 | 2024 | Lynparza |
| Smith+Nephew, INC. | $17.26 | 2024 | Stravix |
| Pfizer INC. | $16.44 | 2024 | |
| Convatec INC. | $16.43 | 2022 | |
| Coloplast Corp | $14.76 | 2025 | |
| Laborie Medical Technologies Corp. | $14.36 | 2024 | Endosheath Technology |
| Organogenesis INC. | $14.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Ideker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.